HEART SENTRY - By lexingtonBioSciences.com

Lexington Bio Sciences new :Heart Sentry"!

Wednesday, February 28, 2018

Lexington BoiSciences "Heart Sentry" Device may be the answer to pre-detection of heart disease!

Lexington Bio Sciences (LexingtonBioSciences.com)


Heart Disease and Heart Attacks are the number one killer of North Americans, and most people, worldwide. Nearly 1 in 3 deaths in the USA alone are attributed to Heart Attack and Stroke!

For 50% of these people, their "first" indication of a problem is a massive heart attack.  They have no warning whatsoever.

Though taking blood pressure and heart rates coupled with ultrasound techniques will sometimes indicate a problem, the fact remains that, only in 50% of all cases do these indicators work. Now, wouldn't it be great if there was a "Non-invasive" way of determining, with a lot more accuracy, if heart disease is prevalent in a patient, "before" the onset of a heart attack? Hey, wouldn't it be great if that test was no more bother than simply taking your blood pressure is?

Well, at this writing, there is such a device, currently in Clinical Trials, after 15 years of research and development in California Universities. Lexington BioSciences "HeartSentry" can measure something that has never been measured properly before. Endothelium

Endothelium, are the cells that line all arteries and are critical to the prevention of atherosclerosis, heart disease and stroke, the two leading causes of deaths worldwide (17.5 million people every year). 
The significant value of measuring endothelial function is supported by many peer-reviewed studies.

For ease of use this new, life saving technology has been incorporated into a simple blood pressure cuff.  Utilizing both blue tooth and cloud technology, the device to provide up-to-date, accurate readings of a patients complete cardiovascular health via electronic monitoring.

As you might expect, this is a significant development in a  multi-billion dollar market, and all the patents and the technology are owned by a MicroCap Business, owned and operated by PHD's - LexingtonBioSciences 

 More about HeartSentry.....

Disclosure: We own LNB Stock! 
Question: Do you? 

Behind Every Successful Company is an Elite Management Team

The principals, directors and advisers of Lexington Biosciences, Inc. (OTC: LXGTF) have been individually and collectively involved in raising extensive capital funding for their private and public companies. Team members have held numerous executive leadership positions encompassing biotechnology, and medical device companies, as well as multi-national corporations. The team includes inventors, scientists, and business people who have successfully started, built and grown multiple life science companies.

Eric Willis, Chief Executive Officer

Mr. Willis is an entrepreneurial healthcare technology executive with a track record of success in bringing products from initial concept to market. He is the past President and Chief Operating Officer of ParaPatch (2013–2015), where he was responsible for the development and launch of an over-the-counter women’s health product for the treatment of urinary incontinence. Prior to this, he served as President and CEO of InSite Medical Technologies (2008–2013) a venture backed start-up medical device company that developed a new method for performing epidural anesthesia. From 1994–2008 he served in a variety of executive and operational roles for cardiovascular medical device companies.

Doug Janzen, Chairman

Mr. Janzen has 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Mr. Janzen is currently Co-Founder and Managing Director of Northview Ventures. He serves as img alt Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, he was President and CEO of Cardiome Pharma (NASDAQ: CRME) During this time he raised over $300 million from investors, completed over $1 billion in licensing deals.

Greg Robertson, M.D., Medical Advisor

Dr. Greg Robertson is chief of the Emory Heart and Vascular Clinic at Johns Creek. At the Emory Johns Creek Hospital he is chief of cardiology and the medical director of the cardiac catheterization laboratory and interventional program. He is board certified in Vascular Medicine, Endovascular Medicine, Interventional Cardiology and Cardiovascular Medicine. He is an associate professor of medicine at Emory University. Dr. Robertson’s clinical expertise has focused on preventative care and using minimally-invasive vascular and cardiac treatment.

Rocco Rossi, Director

A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. His unique blend of experience intersects general management, philanthropy, public policy, politics, business strategy, and new media. As CEO of the Heart and Stroke Foundation – one of Canada’s largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over $500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP.

We believe Opportunity is Knocking

It’s not everyday you are presented with the opportunity of investing in a company that’s within a $140-billion-dollar sector, with a real chance for FDA approval, the potential opportunity to sell their product within some of the largest big box retailers on the planet, the chance to capitalize off of a hot sector with public companies currently making triple digit gains in less than 2 years & not to mention you get to be a part of the beginnings of a company that’s primary goal is to SAVE LIVES!


H. Pelham said...

It's April 2018 and we are still accumulating shares of Lexington Bio Sciences Stock!

H. Pelham said...

It's May - Still buying Lexington Bio Sciences Stock on the dips!

H. Pelham said...

Bought more LNB Stock today on TSX on dip!
Bought more GGG Stock today on TSX!

Investing in the future, for pennies on the dollar!

Retire.Fund said...

July bought more Lexington Bio Sciences shares
After they received Patent approval for their HeartSentry!

Retire.Fund said...

We,ve topped up our LNB stock at .10c PS - Patience is a virtue in investing!

H. Pelham said...

LNB Stock is up over 50% in first week of trading 2019....Your Welcome!!!

Retire Fund said...

Bought more LNB Shares today - don't want to play "catch up" once FDA approves the *HeartSentry*!